

Supplementary Table 3. Survival characteristics of 15 studies in the validation data set*

Study	No. of person-years at risk	Median time at risk, y (range)	Median follow-up time, y (range)	Median entry time†, y (range)	No. of deaths	Annual mortality rate
BBCC	5,046.53	4.56 (0.02-15.00)	5.55 (0.69-15.00)	1.02 (0.00-14.75)	179	0.035
CGPS	6,016.34	3.17 (0.003-5.61)	3.34 (0.003-15.00)	0.00 (0.00-14.89)	275	0.046
CNIO-BCS	652.89	3.33 (0.01-4.54)	5.79 (1.33-15.00)	2.51 (0.00-12.59)	8	0.012
GESBC	2,399.22	4.59 (0.01-7.65)	5.21 (0.24-7.72)	0.20 (0.00-6.43)	95	0.040
HEBCS	12,686.52	5.04 (0.03-15.00)	5.67 (0.08-15.00)	0.00 (0.00-13.69)	386	0.030
KARBAC	2,894.42	6.41 (0.41-8.41)	6.41 (0.41-8.41)	0.00 (0.00-0.00)	89	0.031
KBCP	4,123.14	9.98 (0.08-15.00)	9.98 (0.08-15.00)	0.00 (0.00-0.00)	207	0.050
kConFab/AOCS	904.40	3.29 (0.01-9.51)	8.20 (0.22-15.00)	3.85 (0.00-14.91)	22	0.024
MCBCS	2,596.05	2.38 (0.01-6.98)	2.47 (0.02-6.98)	0.08 (0.00-2.59)	46	0.018
MCCS	4,854.98	7.08 (0.13-15.00)	7.08 (0.13-15.00)	0.00 (0.00-0.00)	75	0.015
ORIGO	2,969.05	6.52 (0.19-10.36)	7.22 (0.36-11.75)	0.34 (0.00-4.59)	117	0.039
PBCS	7,943.03	4.71 (0.07-7.69)	4.96 (0.15-7.72)	0.16 (0.00-3.54)	257	0.032
SASBAC	5,350.06	4.79 (0.03-7.16)	9.35 (4.00-10.60)	4.82 (3.27-6.55)	148	0.028
SBCS	1,826.47	2.76 (0.09-5.42)	5.29 (0.72-15.00)	2.14 (0.00-14.97)	91	0.050
UCIBCS	9,756.52	10.45 (0.03-13.48)	11.78 (0.29-13.80)	1.18 (0.29-10.8)	308	0.032
TOTAL	70,019.63	4.61 (0.003-15.00)	5.29 (0.003-15.00)	0.11 (0.00-14.97)	2,303	0.033

* BBCC = Bavarian Breast Cancer Cases and Controls; CGPS = Copenhagen Breast Cancer Study and General Population Study; CNIO-BCS = Spanish National Cancer Centre Breast Cancer Study; GESBC = Genetic Epidemiology Study of Breast Cancer by Age 50; HEBCS = Helinski Breast Cancer Study; KARBAC = Karolinska Breast Cancer Study; KBCP = Kuopio Breast Cancer Project; kConFab/AOCS = Kathleen Cunningham Foundation Consortium for Familial Breast Cancer (kConFab) and Australian Ovarian Cancer Study (AOCS); MCBCS = Mayo Clinic Breast Cancer Study; MCCS = Melbourne Collaborative Cohort Study; ORIGO = Leiden University Medical Centre Breast Cancer Study; PBCS = National Cancer Institute Polish Breast Cancer Study; SASBAC = Singapore and Sweden Breast Cancer Study; SBCS = Sheffield Breast Cancer Study; UCIBCS = University of California at Irvine Breast Cancer Study.

†Median entry time refers to the median value of time to enrollment, in years, for each study.